---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093342"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:12:20.131653+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics Q2 net loss $33.7M; gets FDA Breakthrough Therapy Designation for atacicept in IgAN

## Summary
- Net loss $33.7M ($0.62/diluted share) vs $20.2M ($0.46) in Q2 2023; cash $384.4M sufficient through approval and US launch.
- FDA granted Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN).
- Phase 2b ORIGIN data: atacicept stabilized kidney function through 72 weeks, reduced hematuria; 96-week data expected Q4 2024.
- Phase 3 ORIGIN 3 enrollment on track to complete Q3 2024; topline data expected Q2 2025.
- Appointed David L. Johnson COO, Amit Sharma EVP Medical Affairs; Christy J. Oliger to board.

## SEC filing metadata
- accession: 0000950170-24-093342
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000095017024093342/0000950170-24-093342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000095017024093342/vera-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093342
- JSON: https://secwatch.observer/filing/0000950170-24-093342.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.